Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

Presentation TCT 2025

TCT 60: Acute-phase Lipid-lowering Effects of Evolocumab in Patients with AMI; Pre-specified Secondary Analysis of the EVO-STEMI Trial

Presenter: Hyun-Jong Lee

October 28, 2025

Presentation TCT 2025

TCT 481: Strike Early, Strike Strong—But Retest Early as Well: Two-Week LDL-C Assessment Accurately Identifies Non-Responders to Triple Oral Lipid-Lowering Therapy in ACS Patients Undergoing PCI

Presenter: Kunal Mahajan

October 27, 2025

Presentation TCT 2025

TCT 475: Impact of Elevated Lipoprotein(a) on LDL Cholesterol Target Attainment Following PCI for Acute Coronary Syndrome Despite Intensive Triple Oral Lipid-Lowering Therapy: A Retrospective Cohort Study

Presenter: Kunal Mahajan

October 27, 2025

Presentation AHA 2024

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Presenter: Kausik K. Ray

November 17, 2024

Presentation TCT 2024

TCT 765: Lipid-Lowering Therapy in Contemporary PCI Practice

Presenter: Patrick Serruys

October 30, 2024

Presentation TCT 2024

TCT 764: Clinical Outcomes of High Intensity Lipid Lowering Therapy in Patient Following Complex PCI

Presenter: Young-Kwan Kim

October 30, 2024

Presentation TCT 2024

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

Presenter: Ryo Hikida

October 29, 2024

Presentation TCT 2024

Beyond Antithrombotics: Lipid-Lowering and Anti-Inflammatory Therapies Post MI

Presenter: Jennifer Rymer

October 29, 2024

Presentation TCT 2024

Early Lipid Lowering Therapy and Glycemic Control Agents: What’s Their Benefit in PAD Intervention

Presenter: Naomi Hamburg

October 29, 2024

Presentation TCT 2024

Lipid-Lowering Therapies for High-Risk Patients: Act Early and Target Aggressively

Presenter: Marc Bonaca

October 28, 2024

Presentation ACC 2024

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

Presenter: Eric Quinton Klug

April 07, 2024

Presentation TCT 2023

TCT 461: Suboptimal Lipid Lowering Treatment After Complex PCI in Contemporary Practice

Presenter: Denise Peeters

October 25, 2023

Presentation ESC 2017

Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South Africa, Middle East and China

Presenter: Anselm K. Gitt

August 30, 2017

Presentation TCT 2016

Hot Topic #2: Lipid Lowering Targets and the Potential Role of the PSCK9 Inhibitors in Routine Clinical Practice

Presenter: Bernard J. Gersh, Felix Mahfoud, Evan A. Stein

November 01, 2016

Presentation TCT 2016

TCT 96: Progression of Coronary Atherosclerosis Despite Lipid-Lowering Therapy in Diabetic Patients Compared to Non-Diabetic Ones. Study With 3D Intravascular Ultrasound and Virtual Histology

Presenter: Farouc Jaffer, Amir Lerman, Tomas Kovarnik

October 31, 2016

Presentation TCT 2015

TCT 80: Favorable Effect of Optimal Lipid-Lowering Therapy on Neointimal Tissue Characteristics After Drug-Eluting Stent Implantation Qualitative Optical Coherence Tomographic Analysis

Presenter: Lisa K. Jennings, Neal S. Kleiman, Ji-Yong Jang

October 13, 2015

Presentation

Impact of Dual Lipid Lowering With Ezetimibe and Atorvastatin on Plaque Regression in PCI Patients

Presenter: K. Tsujita

July 28, 2015

Presentation TCT 2014

LpPLA2 Inhibition by Darapladib in Coronary Artery Disease: Game Over or Just Beginning?

Presenter: Ori Ben-Yehuda, Harvey D. White, Roxana Mehran

September 15, 2014

Presentation TCT 2014

Intravenous HDL to Regress Plaque

Presenter: Ori Ben-Yehuda, Harvey D. White, Roxana Mehran

September 15, 2014

Presentation TCT 2014

PCSK9 Inhibitors: Comparison of Agents and a Systematic Review

Presenter: Ori Ben-Yehuda, Harvey D. White, Roxana Mehran, Evan A. Stein

September 15, 2014

Advertisement

TCT 60: Acute-phase Lipid-lowering Effects of Evolocumab in Patients with AMI; Pre-specified Secondary Analysis of the EVO-STEMI Trial

TCT 481: Strike Early, Strike Strong—But Retest Early as Well: Two-Week LDL-C Assessment Accurately Identifies Non-Responders to Triple Oral Lipid-Lowering Therapy in ACS Patients Undergoing PCI

TCT 475: Impact of Elevated Lipoprotein(a) on LDL Cholesterol Target Attainment Following PCI for Acute Coronary Syndrome Despite Intensive Triple Oral Lipid-Lowering Therapy: A Retrospective Cohort Study

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

TCT 765: Lipid-Lowering Therapy in Contemporary PCI Practice

TCT 764: Clinical Outcomes of High Intensity Lipid Lowering Therapy in Patient Following Complex PCI

TCT 1021: Remaining Cholesterol Crystals Against Lipid-Lowering Therapy as a Residual Risk

Beyond Antithrombotics: Lipid-Lowering and Anti-Inflammatory Therapies Post MI

Early Lipid Lowering Therapy and Glycemic Control Agents: What’s Their Benefit in PAD Intervention

Lipid-Lowering Therapies for High-Risk Patients: Act Early and Target Aggressively

Randomized, Double-blind, Placebo-controlled, Phase 3, Study To Evaluate Lerodalcibep Long-term Efficacy And Safety In Patients With, Or At Very-high Or High Risk, For Cardiovascular Disease On Stable Lipid-lowering Therapy

TCT 461: Suboptimal Lipid Lowering Treatment After Complex PCI in Contemporary Practice

Undertreatment of Female Patients in Lipid-Lowering for Secondary Prevention in Europe, Canada, South Africa, Middle East and China

Hot Topic #2: Lipid Lowering Targets and the Potential Role of the PSCK9 Inhibitors in Routine Clinical Practice

TCT 96: Progression of Coronary Atherosclerosis Despite Lipid-Lowering Therapy in Diabetic Patients Compared to Non-Diabetic Ones. Study With 3D Intravascular Ultrasound and Virtual Histology

TCT 80: Favorable Effect of Optimal Lipid-Lowering Therapy on Neointimal Tissue Characteristics After Drug-Eluting Stent Implantation Qualitative Optical Coherence Tomographic Analysis

Impact of Dual Lipid Lowering With Ezetimibe and Atorvastatin on Plaque Regression in PCI Patients

LpPLA2 Inhibition by Darapladib in Coronary Artery Disease: Game Over or Just Beginning?

Intravenous HDL to Regress Plaque

PCSK9 Inhibitors: Comparison of Agents and a Systematic Review

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content